Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
Behind the stellar launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug make it more complicated to pull it from the market if we find out next year that it doesn’t work? → Read More
Pfizer said it is acquiring Seagen, a maker of targeted cancer drugs, for $43 billion. → Read More
The FDA has approved the first treatment for Rett syndrome, a genetic disease mostly affecting girls that causes severe neurologic impairments. → Read More
Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech companies, failed on Friday. Now biotech startups are left wondering: Who’s going to finance the industry? → Read More
Who invented CRISPR 2.0? What happens when a drug company actually lowers prices? And is Novavax going to survive? STAT's podcast covers all that and more. → Read More
The Food and Drug Administration approved the first drug to treat Friedreich’s Ataxia, a rare, neurological disease. → Read More
The new head of the FDA's Office of Neuroscience is stepping into an increasingly powerful position at the agency. → Read More
Billy Dunn, who presided over the polarizing approval of the Alzheimer’s disease treatment Aduhelm, is leaving the FDA after more than 15 years at the agency. → Read More
For investors, an FDA rejection of Cytokinetics' heart drug would, perhaps unexpectedly, be a welcome relief. → Read More
What makes a drug quintuple in cost? How do you follow inventing a Covid-19 vaccine? And what did we learn from biotech's unicorn era? Find out on the latest episode of "The Readout LOUD." → Read More
The official end of Rubius Therapeutics marks one of biotech’s highest-profile flameouts. → Read More
An experimental antibody that delivers lethal radiation directly to the bone marrow improved the outcomes of stem cell transplants for older patients with relapsed leukemia — and may change the way transplant medicine is practiced. → Read More
The FDA approved the first treatment for geographic atrophy, a progressive eye disease and a leading cause of blindness in older people. → Read More
Christi Shaw, the CEO of Gilead’s Kite Pharmaceuticals cell therapy unit, is leaving the company, Gilead said Friday in a statement. → Read More
Will Dunn apply the doctrine of “regulatory flexibility” to a medicine with less-than-convincing clinical data? → Read More
Vas Narasimhan has been CEO of Novartis since 2018. He talked with STAT about the industry's struggles in Washington, the future of Novartis, and whether the biotech sector is still a little overvalued. → Read More
Is the pharmaceutical lobby on the ropes? What does it mean when a vaccine is "free"? And does biotech prepare you for the presidency? All that and more on the new episode of "The Readout LOUD." → Read More
“We have two major products to launch ... that’s not an opportunity you have very often," said Biogen CEO Chris Viehbacher. → Read More
The CAR-T cancer therapy called Abecma reduced the risk of multiple myeloma relapse by half compared to standard treatment. → Read More
Just how alarming is bird flu? And did we learn enough from Covid-19 to be sensible about it? All that and more on the new episode of "The Readout LOUD" podcast. → Read More